 Interleukin-23 Subunit p19
"Interleukin-23 Subunit p19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subunit of interleukin-23. It combines with INTERLEUKIN-12 SUBUNIT P40, which is shared between the two cytokines, to form in the active interleukin-23 cytokine.
| Descriptor ID |
D053760
|
| MeSH Number(s) |
D12.644.276.374.465.759.500 D12.776.467.374.465.759.500 D23.529.374.465.759.500
|
| Concept/Terms |
Interleukin-23 Subunit p19- Interleukin-23 Subunit p19
- Interleukin 23 Subunit p19
- Interleukin-23 alpha Subunit
- Interleukin 23 alpha Subunit
- alpha Subunit, Interleukin-23
- IL-23p19
- IL-23 p19
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-23 Subunit p19".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-23 Subunit p19".
This graph shows the total number of publications written about "Interleukin-23 Subunit p19" by people in this website by year, and whether "Interleukin-23 Subunit p19" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 | | 2018 | 0 | 2 | 2 | | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-23 Subunit p19" by people in Profiles.
-
Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
-
Serrano L, Maloney V, Gordon KB. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
-
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
-
Mastracci TL, Turatsinze JV, Book BK, Restrepo IA, Pugia MJ, Wiebke EA, Pescovitz MD, Eizirik DL, Mirmira RG. Distinct gene expression pathways in islets from individuals with short- and long-duration type 1 diabetes. Diabetes Obes Metab. 2018 08; 20(8):1859-1867.
-
Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA. An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|